Nuo Therapeutics director exercises options, gains 55,000 shares

Nuo Therapeutics director reports option exercise and share withholding A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025.

Rhea-AI Filing Summary

Nuo Therapeutics director reports option exercise and share withholding

A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025. The director exercised an option to purchase 68,750 shares of common stock at an exercise price of $0.4 per share, receiving 55,000 shares on a net basis. The issuer withheld 13,750 shares of common stock underlying the option to cover the exercise price, using the closing price of $2.00 per share. Following these transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.

Insider Trade Summary

68,750 shares exercised/converted

Exercise 3 txns

Insider WINZER C ERIC

Role Director

Type	Security	Shares	Price	Value
Exercise	Option to purchase common stock	68,750	$0.00	$0.00
Exercise	Common Stock	68,750	$0.40	$28K
Exercise Price or Tax Liability	Common Stock	13,750	$2.00	$28K

Holdings After Transaction: Option to purchase common stock — 0 contracts (Direct); Common Stock — 172,654 shares (Direct)

Footnotes (1)

1. F1. Represents a net exercise of outstanding stock options. The reporting person received 55,000 shares of common stock on the net exercise of option to purchase 68,750 shares of common stock. The issuer withheld 13,750 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuo Therapeutics (AURX) report in this Form 4?

A director of Nuo Therapeutics, Inc. reported exercising an option to purchase 68,750 shares of common stock on 12/17/2025, with shares withheld to cover the exercise price.

How many Nuo Therapeutics (AURX) shares did the director receive from the option exercise?

The director received 55,000 shares of common stock after a net exercise of options covering 68,750 shares.

What exercise price and stock price were used in the Nuo Therapeutics (AURX) option transaction?

The option had an exercise price of $0.4 per share, and the issuer used the closing price of $2.00 per share to determine the value of 13,750 withheld shares to pay the exercise price.

How many Nuo Therapeutics (AURX) shares were withheld to pay the option exercise price?

The issuer withheld 13,750 shares of common stock underlying the option to pay the exercise price, based on the closing price of $2.00 per share.

What is the director’s shareholding in Nuo Therapeutics (AURX) after the reported transactions?

After the reported transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.

What is the relationship of the reporting person to Nuo Therapeutics (AURX)?

The reporting person is a director of Nuo Therapeutics, Inc., as indicated on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/22/2025 - 11:53 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WINZER C ERIC

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TX 77054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		M		68,750	A	$0.4	186,404	D
Common Stock	12/17/2025		F(1)		13,750	D	$2	172,654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$0.4	12/31/2025		M			68,750	12/31/2018	12/31/2025	Common Stock	68,750	$0	0	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 55,000 shares of common stock on the net exercise of option to purchase 68,750 shares of common stock. The issuer withheld 13,750 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.00.

	/s/ David Jorden, attorney-in-fact	12/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.